IPO - Kenvue Inc.

Form Type: 10-K

Filing Date: 2025-02-24

Corporate Action: Ipo

Type: New

Accession Number: 000194404825000033

Filing Summary: Kenvue Inc. filed a 10-K with detailed information regarding their initial public offering (IPO) that took place recently. The document outlines the company’s business operations, financial performance, risk factors, management's discussion, and corporate governance. It highlights Kenvue's position in the consumer health sector and includes financial statements reflecting performance metrics. The filing includes disclosures related to the amount raised in the IPO, the interests of management and major shareholders, and future growth strategies. The offering marks a significant milestone for Kenvue as it transitions from a subsidiary to an independent publicly traded entity, focusing on enhancing shareholder value while maintaining operational efficiency and effective market competition.

Document Link: View Document

Form Type: S-3ASR

Filing Date: 2025-02-24

Corporate Action: Ipo

Type: New

Accession Number: 000162828025007391

Filing Summary: On February 24, 2025, Kenvue Inc. filed a registration statement on Form S-3ASR with the SEC. This registration statement enables Kenvue to sell various types of securities over time. The company, incorporated in Delaware, is focused on providing consumer health products, having separated from Johnson & Johnson in August 2023. The statement outlines the offerings that may include senior debt securities, preferred stock, common stock, depositary shares, and warrants. Kenvue reported net sales of $15.5 billion for the fiscal year 2024 and emphasized its commitment to consumer health through innovative strategies and robust marketing efforts. The document includes a commitment to disclose risk factors associated with investment options and use of proceeds from sales for general corporate purposes, debt repayment, and potential acquisitions.

Document Link: View Document